Process Development

We offer comprehensive process development services designed to seamlessly transition your research-grade process into a scalable, cGMP-compliant manufacturing process.

  • Process optimization for Suspension and Adherent leveraging scale-down models
  • Optimization for increased yield/recovery, full capsid separation and specific purity requirements
  • Focus on reproducibility, scalability and transferability to cGMP manufacturing

Critical factors for optimization

upstream optimization icon
Upstream Optimization
  • Cellular Factors
  • Media Factors
  • Transfection Reagent
  • DNA Factors
  • Harvest Factors
bioreactor icon
Downstream Optimization
  • Clarification Factors
  • Ultrafiltration/Diafiltration Factors
  • Chromatography Factors Including Column Chemistries
  • DNA Factors
  • Ultracentrifugation
formulation optimization icon
Formulation Optimization
  • Formulation Buffer Factors
Powering Your Science

Our Approach

Data driven process optimization leveraging decades of production data to minimize number of process parameters and conditions that need to be assessed.

Highly-interactive, consultative approach
QbD mindset based on multifactorial DoE strategy
Ambr® 250 system and flask available for DoEs
50L & 200L bioreactors available for scale-up studies
Supported by high-throughput analytics
Process optimization for plasmids from development through scale-up

Enabling Your Program

Andelyn Feasibility Study

Andelyn's small-scale feasibility studies enable you to generate data that drive decisions and help draft your manufacturing roadmap from GMP to commercial scale.

feasibility chart
*Actual timeline and parameters may vary depending on process requirements and material availability

Hear from Our Partners

Success Stories
Learn More About Us
“Working with Andelyn was a great choice given their history with the product, their extensive multi-product experience with the manufacturing technology used for the product, and our desire to quickly bring UX111 to MPS IIIA patients.”
Dennis Huang
Chief Technical Operations Officer and EVP, Gene Therapy Research and Development
Ultragenyx
“Purespring is excited to build on our longstanding working relationship with Andelyn to accelerate the preclinical and clinical manufacture of our innovative AAV-based gene therapies.”
Julian Hanak
CEO
Purespring Therapeutics

Andelyn Development Center

Explore the heart of innovation at the Andelyn Development Center (ADC), where groundbreaking research, meticulous process development, and advanced analytical capabilities converge. As the cornerstone of Andelyn’s capabilities, ADC expands horizons and meets the evolving demands of our clients.

Explore the Facility
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.